413 related articles for article (PubMed ID: 27436848)
1. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.
Mei ZB; Duan CY; Li CB; Cui L; Ogino S
Ann Oncol; 2016 Oct; 27(10):1836-48. PubMed ID: 27436848
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
4.
Jin J; Shi Y; Zhang S; Yang S
Acta Oncol; 2020 Jan; 59(1):66-74. PubMed ID: 31545109
[No Abstract] [Full Text] [Related]
5.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis.
Fang T; Liang T; Wang Y; Wu H; Liu S; Xie L; Liang J; Wang C; Tan Y
BMC Gastroenterol; 2021 Jul; 21(1):297. PubMed ID: 34301194
[TBL] [Abstract][Full Text] [Related]
7. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
8. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
9. No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.
Ge XQ; Yang YZ; Li SS; Hou L; Ren JL; Yang KP; Fa XE
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):462-468. PubMed ID: 28585132
[TBL] [Abstract][Full Text] [Related]
10. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.
Yang ZY; Wu XY; Huang YF; Di MY; Zheng DY; Chen JZ; Ding H; Mao C; Tang JL
Int J Cancer; 2013 Oct; 133(8):1914-25. PubMed ID: 23494461
[TBL] [Abstract][Full Text] [Related]
11. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
Liao X; Lochhead P; Nishihara R; Morikawa T; Kuchiba A; Yamauchi M; Imamura Y; Qian ZR; Baba Y; Shima K; Sun R; Nosho K; Meyerhardt JA; Giovannucci E; Fuchs CS; Chan AT; Ogino S
N Engl J Med; 2012 Oct; 367(17):1596-606. PubMed ID: 23094721
[TBL] [Abstract][Full Text] [Related]
12. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
13. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract][Full Text] [Related]
14.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
15. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.
Domingo E; Church DN; Sieber O; Ramamoorthy R; Yanagisawa Y; Johnstone E; Davidson B; Kerr DJ; Tomlinson IP; Midgley R
J Clin Oncol; 2013 Dec; 31(34):4297-305. PubMed ID: 24062397
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis.
He L; Li H; Cai J; Chen L; Yao J; Zhang Y; Xu W; Geng L; Yang M; Chen P; Zheng J; Yang Y; Gong S
Cell Physiol Biochem; 2018; 51(3):1237-1249. PubMed ID: 30481755
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
18. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials.
Fillbrunn M; Signorovitch J; André F; Wang I; Lorenzo I; Ridolfi A; Park J; Dua A; Rugo HS
BMC Cancer; 2022 Sep; 22(1):1002. PubMed ID: 36131248
[TBL] [Abstract][Full Text] [Related]
20. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
Zeng Q; Xie L; Zhou N; Liu M; Song X
Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]